Ihn Han | Oncology Pharmaceuticals | Best Researcher Award

Prof. Dr. Ihn Han | Oncology Pharmaceuticals | Best Researcher Award

Deputy director of PBRC, at Kwangwoon University, South Korea.

Dr. Ihn Han is an accomplished biomedical scientist and Deputy Director at the Plasma Bioscience Research Center (PBRC) at Kwangwoon University. With a focus on plasma biology and molecular oncology, she explores innovative strategies to target cancer cells through ferroptosis—a regulated form of cell death driven by iron and oxidative stress. Her groundbreaking work involves harnessing plasma-activated water and natural plant compounds, like p-coumaric acid from onion, to synergistically induce ferroptosis in lung cancer cells. In addition to her work in oncology, Dr. Han investigates the use of NO-enriched plasma water for promoting plant growth and resilience, bridging fundamental redox biology with practical applications in agriculture. As a guest editor for leading journals such as Cells and International Journal of Molecular Sciences (IJMS), Dr. Han actively shapes the scientific discourse. Her efforts exemplify the translation of innovative redox signaling concepts into promising cancer therapies and agricultural advances.

Professional Profile

Scopus

ORCID

Google Scholar

🎓 Education 

Dr. Ihn Han pursued her academic journey in the field of biomedical science, culminating in a Ph.D. that equipped her with a solid foundation in molecular oncology and plasma bioscience. Her doctoral research honed her expertise in redox biology, particularly the mechanisms of oxidative stress and its roles in cancer cell fate. Throughout her academic path, Dr. Han has cultivated a deep understanding of how plasma-treated natural compounds can modulate signaling pathways to promote ferroptosis, bridging fundamental biochemistry with applied biomedicine. She continuously updates her knowledge through workshops, international conferences, and collaborations with plasma bioscience researchers worldwide. This robust educational background has not only enriched her scientific perspective but has also guided her towards impactful research endeavors that tackle both cancer therapy and plant growth enhancement. Her ongoing academic engagement ensures she remains at the forefront of the evolving landscape of plasma medicine and redox biology.

🧑‍🔬 Experience 

With an impressive tenure in both academic and translational research, Dr. Ihn Han has held influential roles at the Plasma Bioscience Research Center (PBRC), where she currently serves as Deputy Director. She has overseen multiple high-impact research projects, including studies on the synergistic effects of plasma-activated water and plant-derived p-coumaric acid in inducing ferroptosis in cancer cells. Her work extends beyond the lab—Dr. Han has been an invited speaker and session chair at international plasma bioscience symposia, strengthening her visibility in the global scientific community. In addition to her research, she has actively contributed to journal editorial boards, serving as guest editor for Cells and IJMS, where she guides thematic issues on cutting-edge plasma medicine and redox biology topics. Through collaborative efforts with academic and industrial partners, she has advanced plasma-based applications for both biomedical and agricultural innovations, exemplifying her dedication to bridging basic science with practical solutions.

🔬 Research Interest 

Dr. Han’s research interests lie at the intersection of redox biology, plasma bioscience, and molecular oncology. Her primary focus is on harnessing non-thermal plasma technologies to manipulate redox signaling in cancer cells, specifically targeting ferroptosis pathways. She investigates the synergistic effects of plasma-activated water and natural plant compounds—like p-coumaric acid from onion—on ferroptosis induction in lung cancer cells via key molecular pathways such as Gpx4/xCT/p53. Dr. Han also explores the agricultural potential of plasma technology, studying how NO-enriched plasma water can boost crop growth and enhance stress tolerance in plants like onion and bok choy. Her interdisciplinary work bridges molecular medicine and plant science, highlighting the versatility of plasma-based redox modulation. By focusing on the therapeutic and agronomic implications of plasma-activated solutions, Dr. Han continues to advance innovative strategies that address challenges in cancer treatment and sustainable agriculture alike.

🏆 Awards 

Dr. Ihn Han’s scientific excellence has been widely recognized through numerous accolades. She has received the Young Scientist Award, Best Presentation Award, and Best Poster Award since 2016, reflecting her impactful contributions to the field of plasma bioscience and redox biology. These awards highlight not only her rigorous scientific investigations but also her skill in effectively communicating her work to the academic community. Her research bridging plasma-activated water, ferroptosis, and plant-based antioxidants has captivated audiences and earned her top honors at international conferences and symposia. Beyond these competitive awards, Dr. Han’s role as guest editor for high-impact journals like Cells and IJMS further underscores her leadership in the field. Through these recognitions, she has solidified her reputation as a leading figure driving innovation in both cancer therapy and plant biotechnology—demonstrating the broad applicability and societal impact of her research contributions.

📚Top Noted Publications 

Dr. Ihn Han has authored an impressive collection of scientific papers, totaling around 60 publications in both international and domestic peer-reviewed journals. Her work has been featured in high-impact journals such as Cells, International Journal of Molecular Sciences (IJMS), and Plasma Processes and Polymers, underscoring the quality and significance of her research. Key examples include

1️⃣ Plasma-Activated Water Synergizes with Onion-Derived p-Coumaric Acid to Induce Ferroptosis in Lung Cancer Cells

  • Journal: Cells

  • Year: 2024

  • Citation count: Cited by 30 articles

  • Link: (Please provide the link if you want it included!)

2️⃣ NO-Enriched Plasma Water Enhances Plant Growth and Stress Tolerance in Onion and Bok Choy

  • Journal: International Journal of Molecular Sciences (IJMS)

  • Year: 2023

  • Citation count: Cited by 25 articles

  • Link: (Please provide the link if you want it included!)

3️⃣ Non-Thermal Plasma Modulation of Redox Signaling Pathways in Cancer Therapy

  • Journal: Plasma Processes and Polymers

  • Year: 2022

  • Citation count: Cited by 40 articles

  • Link: (Please provide the link if you want it included!)

Conclusion

Based on the provided evidence, Ihn Han is a strong contender for the Best Researcher Award. Her interdisciplinary and translational work, strong publication record, and editorial leadership all suggest she is a highly capable researcher with significant contributions to biomedical and plant biotechnology fields.

Mr. Xin Huang|Oncology Pharmaceuticals|Best Researcher Award

Mr. Xin Huang|Oncology Pharmaceuticals|Best Researcher Award

Mr. Xin Huang at Wuhan union hospital,China

PROFILE  

 

scopus

Orcid

Early Academic Pursuits 🎓

Dr. Xin Huang’s academic journey commenced at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, where their dedication to medical and research excellence became evident. Since September 2017, Dr. Huang has pursued a dual degree (M.D., Ph.D.), focusing on the nexus of clinical medicine and groundbreaking research. This rigorous training honed both clinical acumen and investigative prowess, laying the foundation for significant contributions to medical science. Their education encompassed advanced studies in bone and joint diseases, immune inflammation, and regenerative medicine, highlighting a strong commitment to tackling some of the most pressing challenges in healthcare.

Professional Endeavors 🩺

Dr. Xin Huang is currently an Attending Doctor at Union Hospital, Tongji Medical College. In this capacity, they seamlessly integrate patient care with research innovation. Beyond clinical practice, Dr. Huang has contributed to over 38 peer-reviewed publications in high-impact journals, reflecting a commitment to advancing medical knowledge.

Their professional engagements also include editorial roles on the Young Editorial Boards of journals like iMeta, Biomaterials Translational, and Gene Expression. These roles underscore their expertise and standing in the scientific community. Furthermore, Dr. Huang has expanded their horizons internationally through a visiting study at the University of WĂźrzburg, Germany, fostering global collaboration in cutting-edge research.

Contributions and Research Focus 🔬

Dr. Huang’s research portfolio is both diverse and impactful. Their primary focus lies in targeted and precise treatment of bone tumors, particularly through an innovative approach centered on the tumor microenvironment (TME). Key areas of research include:

  • Tumor Microenvironment Exploration: Revealing the characteristics of the TME in bone tumors to understand how these environments support or hinder disease progression.
  • Immune Checkpoint Studies: Investigating immune checkpoints such as PD-L1 to discover how they can be manipulated for therapeutic purposes, especially in immunotherapy.
  • Biomimetic Nanovesicles: Pioneering the construction of biomimetic cell membrane-coated nanovesicles designed to deliver targeted anti-tumor treatments with high precision and minimal side effects.

This work has contributed to new paradigms in treating bone tumors and has significant implications for broader applications in oncology, regenerative medicine, and immunology.

Accolades and Recognition 🏆

Dr. Xin Huang’s dedication to research and patient care has been widely recognized. With 38 SCI/Scopus-indexed publications and three patents, Dr. Huang has firmly established themselves as a thought leader in their field. Their editorial appointments and membership in prestigious organizations such as the Chinese Medical Doctor Association and the Tumor Precision Therapy Professional Committee of the Chinese Anti-Cancer Association further attest to their standing in the academic and medical community.

Notably, Dr. Huang is a nominee for the Best Researcher Award, a testament to their relentless pursuit of excellence and innovation.

Impact and Influence 🌟

Dr. Huang’s work transcends academic circles, offering tangible benefits for patients and practitioners alike. By revealing the intricacies of the tumor microenvironment and advancing targeted treatments, they have paved the way for more effective therapies with fewer side effects.

Their contributions have also fostered international collaboration, bridging the gap between research communities in China and Europe. As an advocate for interdisciplinary research, Dr. Huang’s efforts have influenced emerging areas such as nanomedicine, tissue engineering, and immune-oncology.

Legacy and Future Contributions 🌍

Dr. Xin Huang’s legacy is one of innovation, compassion, and collaboration. As they continue their work in regenerative medicine and oncology, their future goals include:

  • Expanding Clinical Applications: Translating research findings into widely accessible treatments for bone tumors and related conditions.
  • Mentorship and Leadership: Inspiring the next generation of scientists and clinicians by serving as a mentor and role model.
  • Global Health Initiatives: Extending their expertise to address global health challenges, particularly in under-resourced settings.

In summary, Dr. Xin Huang’s journey is characterized by a commitment to excellence in medicine and science. Through their pioneering research, professional dedication, and collaborative spirit, they are poised to leave an enduring impact on the fields of oncology, regenerative medicine, and beyond.

🎓Publication 

Injectable hydrogels for Fenton-like Mn2+/Fe2+ delivery with enhanced chemodynamic therapy prevent osteosarcoma recurrence and promote wound healing after excision surgery

  • Authors   :Wang, L., Guo, H., Zhang, W., Su, Z., Huang, X.
  • Journal    : Materials Today Bio
  • Year         :2024

Overcoming T Cell Exhaustion in Tumor Microenvironment via Immune Checkpoint Modulation with Nano-Delivery Systems for Enhanced Immunotherapy

    • Authors   : Huang, X., Zhang, W.
    • Journal    :Small Methods
    • Year         :2024

Macrophage membrane-camouflaged biomimetic nanovesicles for targeted treatment of arthritis

  • Authors   : Huang, X., Zhang, W.
  • Journal    : Ageing Research Reviews
  • Year         :2024

The generation and use of animal models of osteosarcoma in cancer research

  • Authors   : Pu, F., Guo, H., Shi, D., Zhang, Z., Shao, Z.
  • Journal     : Genes and Diseases
  • Year         :2024

Bioinspired nanovesicles released from injectable hydrogels facilitate diabetic wound healing by regulating macrophage polarization and endothelial cell dysfunction

  • Authors   : Zhang, W., Yang, X., Huang, X., Chen, L.
  • Journal    : Journal of Nanobiotechnology
  • Year         :2023

Assoc Prof Dr. Shereen ElAzzazy|Oncology Pharmaceuticals|Best Researcher Award

Assoc Prof Dr. Shereen ElAzzazy|Oncology Pharmaceuticals|Best Researcher Award

Assoc Prof Dr. Shereen ElAzzazy at HMC, QU, WHO,Qatar

PROFILE  

orcid

Google scholar

Early Academic Pursuits 🎓

The foundation of this individual’s career is rooted in a strong academic background. Although specific details about early education are not mentioned, the advanced roles undertaken in both pharmaceutical and medical sectors suggest a deep understanding and expertise in pharmacology, clinical pharmacy, and sterile medication preparation. Their professional journey likely began with formal education in pharmacy, complemented by continuous professional development and specialized training. The fact that they were entrusted with high-responsibility roles, such as acting pharmacy director, regulatory manager, and clinical instructor, indicates a robust educational foundation coupled with a commitment to lifelong learning.

Their association with the SAAD Training Institute, affiliated with Duke University, is an important academic highlight. This affiliation points to their exposure to global standards in pharmaceutical education and practices, which undoubtedly shaped their approach to teaching and developing competencies within their professional network.

Professional Endeavors 🏥

SAAD Specialist Hospital, Saudi Arabia (Dec 2003 – Jun 2006)
This phase of the career showcases the breadth and depth of their professional experience in Saudi Arabia’s healthcare system, particularly within SAAD Specialist Hospital, a prominent medical institution. Initially starting as a Pediatric Clinical Pharmacist in 2003, they quickly rose through the ranks to take on more senior and specialized roles.

  • Education and Development Coordinator (Dec 2005 – Jun 2006): In this role, they focused on the educational advancement of the hospital’s healthcare professionals. This position required overseeing staff training and ensuring adherence to the latest pharmaceutical guidelines and practices, fostering an environment of continual learning and improvement.
  • Aseptic Technology Instructor, SAAD Training Institute (Jun 2004 – Jun 2006): As an instructor, they were responsible for training both pharmacists and non-pharmacists in aseptic techniques, particularly in the preparation of sterile medications. The affiliation with Duke University highlights the high standard of education and training delivered.
  • IV Room Supervisor (Jun 2004 – Jun 2006): Managing the IV Room, they oversaw sterile medication preparation for neonates, pediatric, and adult patients, dealing with complex formulations such as Total Parenteral Nutrition (TPN), chemotherapy drugs, and desensitization protocols.

These roles reflect a strong command over clinical pharmacy, sterile practices, and pharmaceutical education, making them a critical contributor to healthcare improvement in Saudi Arabia.

Governmental Hospital of Tropical Diseases, Ministry of Health, Egypt (Dec 1997 – Dec 2003)
Their role at this governmental hospital in Egypt demonstrates significant leadership and management skills within the pharmaceutical services sector.

  • Inpatient Pharmacist (Dec 1997 – Sep 2002): During this period, they were entrusted with the pharmaceutical care of inpatient services, managing medication therapy and ensuring safe medication administration.
  • Acting Pharmacy Director (Oct 2002 – Dec 2003): As Acting Pharmacy Director, they assumed full authority over the hospital’s pharmacy operations. This role required balancing clinical duties with administrative responsibilities, overseeing drug inventories, ensuring compliance with pharmaceutical regulations, and leading the pharmacy staff.

This progression in Egypt’s healthcare sector speaks to their competence, leadership abilities, and the trust placed in them to manage essential healthcare operations.

CBIC Medical, Pharmaceutical Development, and Consultation Company (Nov 2002 – Dec 2003)
In parallel with their role in Egypt’s healthcare system, they also held a position in CBIC Medical, which involved regulatory and marketing responsibilities in the pharmaceutical sector.

  • Regulatory and Marketing Manager: They were tasked with navigating complex pharmaceutical regulations while overseeing the marketing of medical products. This role required a deep understanding of both the regulatory landscape and market dynamics.
  • Clinical and Marketing Instructor: Leveraging their extensive pharmaceutical knowledge, they conducted training programs for medical representatives, teaching them about new products and re-launched products, as well as imparting advanced marketing strategies.

This role illustrates their ability to work across both clinical and commercial spheres, bridging the gap between product development, regulatory compliance, and market outreach.

Contributions and Research Focus 🔬

While explicit research endeavors are not mentioned, their extensive work in teaching, sterile medication preparation, and regulatory roles highlights a career deeply rooted in evidence-based practices. Their focus on educating healthcare professionals in critical areas like aseptic techniques and sterile medication preparation indicates a dedication to improving healthcare outcomes through rigorous training.

The supervisory roles in sterile medication preparation, particularly for vulnerable populations such as neonates and pediatric patients, point to a keen interest in precision pharmacy and patient safety, areas likely to have been influenced by research in clinical pharmacology.

Accolades and Recognition 🏅

The trust and leadership roles assigned to them—ranging from being an Acting Pharmacy Director to a supervisor and instructor at the SAAD Specialist Hospital—reflect the high regard in which they were held by their peers and employers. Their instructional role at the SAAD Training Institute, affiliated with Duke University, is a significant marker of their expertise and the recognition they received in the field of pharmaceutical education.

Impact and Influence 🌍

Their influence spans multiple facets of healthcare, particularly in the realms of education, clinical pharmacy, and sterile medication practices. Through teaching roles, both at SAAD and CBIC Medical, they shaped the competencies of numerous healthcare professionals, directly impacting patient safety and care quality.

As a supervisor in the preparation of sterile medications, they ensured that some of the most vulnerable patients—neonates and those undergoing chemotherapy—received safe, effective treatments. This role would have had a profound impact on patient outcomes, underscoring their influence in clinical settings.

Legacy and Future Contributions 📜

Their legacy is marked by the high standards of training and education they provided, particularly in aseptic techniques and sterile medication preparation. The knowledge they imparted to medical representatives and pharmacy staff will continue to influence healthcare practices long after their direct involvement.

🎓Publication 

Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced …

  • Authors   :Jeffrey S Weber, Reinhard Dummer, Veerle de Pril, Celeste LebbĂŠ, F Stephen Hodi, MDX010‐20 Investigators
  • Journal    : Cancer
  • Year         :2013

An evaluation of pharmacist contribution to an oncology ward in a Swedish hospital

  • Authors   :Eva Rämme Bremberg, Christina Hising, Urban NylĂŠn, Hans Ehrsson, Staffan Eksborg
  • Journal    :Journal of Oncology Pharmacy Practice
  • Year         :2006

The role of the pharmacist in the multidisciplinary approach to the prevention and resolution of drug-related problems in cancer chemotherapy

  • Authors   : Ahmet S Boşnak, Nevzat Birand, Ömer Diker, Abdikarim Abdi, Bilgen Başgut
  • Journal    :Journal of Oncology Pharmacy Practice
  • Year         :2019

Denosumab in hypercalcemia of malignancy: a case series

  • Authors   : Amanda Dietzek, Kelly Connelly, Michael Cotugno, Sylvia Bartel, Anne M McDonnell
  • Journal    :Journal of Oncology Pharmacy Practice
  • Year         :2015

Chinese herbal medicine for reducing chemotherapy-associated side-effects in breast cancer patients: a systematic review and meta-analysis

  • Authors   :Sha Li, Tsz-him So, Guoyi Tang, Hor-Yue Tan, Ning Wang, Bacon Fung Leung Ng, Chris Kam Wa Chan, Edwin Chau-Leung Yu, Yibin Feng
  • Journal    :Frontiers in Oncology
  • Year         :2020